Welcome to our dedicated page for CervoMed news (Ticker: CRVO), a resource for investors and traders seeking the latest updates and insights on CervoMed stock.
CervoMed Inc. reports clinical-stage biotechnology developments centered on neflamapimod, an oral small-molecule drug candidate for age-related brain disorders. Company news most often covers dementia with Lewy bodies, the Phase 2b RewinD-LB trial, biomarker and MRI analyses, pharmacokinetic work, formulation and dosing disclosures, and regulatory interactions tied to later-stage development.
Updates also include financial results, grant revenue trends, investor conference presentations, shareholder voting matters, governance items, and capital-structure disclosures. CervoMed has also reported neflamapimod's inclusion in the UK EXPERTS-ALS platform for amyotrophic lateral sclerosis research.
CervoMed (NASDAQ: CRVO) announced on Feb 18, 2026 that neflamapimod was selected for inclusion in the UK EXPERTS-ALS platform to evaluate potential ALS treatments.
The randomized, multicenter, open-label trial will measure neurofilament light chain (NfL) in blood; initial evaluation targets ~35 patients for 18–24 weeks, with potential expansion to 80. Trial costs are funded by the UK NIHR and major motor neuron disease charities; first dosing expected by end of 2026.
CervoMed (NASDAQ: CRVO) reported late-breaking Phase 2b RewinD-LB results showing neflamapimod significantly slowed clinical progression in dementia with Lewy bodies (DLB) and reduced the biomarker plasma GFAP. In an extension phase using a new capsule batch (DP Batch B), CDR-SB worsening was 52% lower versus DP Batch A at week 16 (and 82% lower in patients with ptau181 <21 pg/mL). Effects were durable to 32 weeks and correlated with GFAP reductions (median -16.0; p<0.0001). Initial randomized phase did not meet the primary endpoint due to lower-than-expected bioavailability with DP Batch A. CervoMed plans a Phase 3 registrational trial in H2 2026.
CervoMed (NASDAQ: CRVO) presented Phase 2b RewinD-LB biomarker data on December 1, 2025 at CTAD showing neflamapimod reduced plasma GFAP, increased the Aβ42/40 ratio, and trended to lower NfL in dementia with Lewy bodies (DLB).
Key controlled comparison used participants who received a higher-bioavailability capsule batch (DP Batch B) during a 32-week open-label extension versus their prior placebo period; GFAP change correlated with clinical CDR-SB change (r=0.35, p=0.036).
CervoMed (NASDAQ: CRVO) announced that neflamapimod will be featured in two presentations at the 18th CTAD conference, Dec 1–4, 2025 in San Diego.
A late-breaking oral presentation on Dec 4, 2:10 p.m. PT will present full results from the Phase 2b RewinD-LB trial at 32 weeks, delivered by Prof. John-Paul Taylor. A poster (Poster 071) on Dec 1–2 reports that neflamapimod significantly lowers plasma GFAP and examines effects on NfL and Aβ42/40. Plasma assays were run at the Neurochemistry Laboratory, Amsterdam UMC under Prof. Charlotte Teunissen.
CervoMed (NASDAQ: CRVO) reported Q3 2025 results and clinical progress on neflamapimod for dementia with Lewy bodies (DLB). The company said it aligned with the FDA on Phase 3 trial design and plans to meet other global regulators before initiating a global pivotal trial in H2 2026. Phase 2b RewinD-LB 32-week data showed a 64% risk reduction in clinically significant worsening (CDR-SB ≥1.5) in patients with low AD co-pathology (p<0.001) and correlated reductions in plasma GFAP biomarker. Cash on hand was $27.3M (Sept 30, 2025), with funding expected into the third quarter of 2026. Q3 net loss was $7.7M.
CervoMed (NASDAQ: CRVO) announced written FDA feedback aligning on key elements of its planned global Phase 3 trial of neflamapimod for dementia with Lewy bodies (DLB).
The company plans a single, randomized, double-blind, placebo-controlled Phase 3 in ~300 DLB patients, starting in the second half of 2026, with 32-week randomized treatment and a 48-week open-label extension. The primary endpoint is change in CDR-SB; participants with Alzheimer’s co-pathology will be excluded by imaging/CSF and a plasma ptau181 cutoff (≥21.0 pg/mL).
CervoMed (NASDAQ: CRVO) appointed David Quigley to its Board of Directors effective Oct 28, 2025. Mr. Quigley is a former Senior Partner at McKinsey & Company who led Life Sciences and Private Capital practices (Senior Partner 2010–2025) and brings strategy, commercial, transaction, and M&A experience.
The appointment aligns with CervoMed’s near‑term corporate priorities: planned Phase 3 in dementia with Lewy bodies (DLB) and anticipated FDA feedback on Phase 3 design in Q4 2025. Management says Quigley’s network and commercial expertise will support Phase 3 planning, partnering, and potential commercialization of neflamapimod following Phase 2b results.
CervoMed (NASDAQ: CRVO) announced that Matthew Winton, Ph.D., Chief Commercial and Business Officer, will present a corporate presentation at the Emerging Growth Conference on Wednesday, October 22, 2025. The virtual presentation is scheduled for 11:25–11:55 AM ET. A live webcast and replay will be available via the provided webcast link and in the Investor section of the CervoMed website.
CervoMed (NASDAQ: CRVO) reported Phase 2b RewinD-LB results on Oct 8, 2025 showing neflamapimod activity in dementia with Lewy bodies (DLB).
In participants with plasma ptau181 <21 pg/mL (low likelihood of Alzheimer’s co-pathology), NFMD/B produced significant within-subject improvement on CDR-SB versus placebo (difference = −1.12, p=0.005) and improved clinical scales during the first 16 weeks of the Extension Phase. NFMD/B reduced risk of clinically meaningful progression by 67% versus NFMD/A over 32 weeks and 75% versus placebo over 16 weeks (both p<0.001).
Plasma GFAP fell with NFMD/B (median −16.7 pg/mL vs +5.8 pg/mL on placebo; median difference −23.1 pg/mL, p=0.016), and GFAP change correlated with CDR-SB change (p=0.036). The company expects FDA feedback on Phase 3 design in Q4 2025.
CervoMed (NASDAQ: CRVO) appointed Matthew Winton, Ph.D., as Chief Commercial and Business Officer on Oct 7, 2025 to strengthen commercialization and corporate growth as the company advances into late‑stage Phase 3 development for neflamapimod in dementia with Lewy bodies (DLB). Dr. Winton brings nearly two decades of CNS commercial experience, including leadership roles at Biogen and Inozyme and involvement in a recent acquisition. CervoMed granted an inducement option for 75,000 shares at an exercise price of $8.62 on Oct 6, 2025 that vests monthly over three years commencing Oct 31, 2025.